Analysis Shows 51.9% Increase in Sales; Hanmi Pharmaceutical Leads Amidst Growing Competition
According to UBIST, outpatient sales of combined medications for 슬롯사이트 업 and hyperlipidemia in South Korea surged by 51.9% in Q1 2023/2024 compared to the same period last year, reaching .13 million. All companies introducing these medications witnessed sales growth.
South Korea currently approves five combined medications for 슬롯사이트 업 and hyperlipidemia, including Amosartan XQ Tab, Rozetelpine, Nuvorozet Tab, Duowell A Plus Tab, and Telmican Q. However, there were no new approvals this year, with Yuhan Corporation focusing on contracted production of its existing medications.
The top-selling product in Q1 2023/2024 was Hanmi Pharmaceutical's Amosartan XQ Tablets, with sales soaring by 32.4% to .2 million. Hanmi's strategy of offering six dosage combinations has been pivotal in expanding treatment options.
Latecomers like GC Biopharma's Rozetelpine and Chong Kun Dang's Nuvorozet Tablets have also witnessed substantial growth, with sales increasing by 180.6% and 141.6%, respectively, compared to the previous year.
Jeil Pharmaceutical's Telmican Q, despite starting with no sales in Q1 2023, recorded ,933 in Q1 2024. The rising prescription volumes reflect increasing physician confidence in prescribing combined medications for 슬롯사이트 업 and hyperlipidemia.
Boryung Pharmaceuticals and Daewoong Pharmaceutical conducted clinical trials for their combined medications last year, hinting at potential future competition in the market.